dc.contributor
Agència de Salut Pública de Catalunya, Departament de Salut, Generalitat de Catalunya, Barcelona, Spain. Ciber of Epidemiology and Public Health (CIBERESP), Madrid, Spain
dc.contributor
Departament de Salut
dc.contributor.author
Plans-Rubió, Pedro
dc.date.accessioned
2025-10-24T10:56:46Z
dc.date.available
2025-10-24T10:56:46Z
dc.date.issued
2024-01-26T09:45:13Z
dc.date.issued
2024-01-26T09:45:13Z
dc.date.issued
2023-12-10
dc.identifier
Plans-Rubió P. Effectiveness of Adapted COVID-19 Vaccines and Ability to Establish Herd Immunity against Omicron BA.1 and BA4-5 Variants of SARS-CoV-2. Vaccines. 2023 Dec 10;11(12):1836.
dc.identifier
https://hdl.handle.net/11351/10912
dc.identifier
10.3390/vaccines11121836
dc.identifier.uri
http://hdl.handle.net/11351/10912
dc.description.abstract
COVID-19 vaccination; SARS-CoV-2; Herd immunity against SARS-CoV-2
dc.description.abstract
Vacunación COVID-19; SARS-CoV-2; Inmunidad colectiva contra el SARS-CoV-2
dc.description.abstract
Vacunació contra la COVID-19; SARS-CoV-2; Immunitat de grup contra SARS-CoV-2
dc.description.abstract
The emergence of novel SARS-CoV-2 variants has raised concerns about the ability of COVID-19 vaccination programs to establish adequate herd immunity levels in the population. This study assessed the effectiveness of adapted vaccines in preventing SARS-CoV-2 infection and the ability of the adapted vaccines to establish herd immunity against emerging Omicron variants. A systematic literature review was conducted to estimate the absolute vaccine effectiveness (aVE) in preventing SARS-CoV-2 infection using adapted vaccines targeting Omicron variants. The ability of the adapted vaccines to establish herd immunity was assessed by taking into account the following factors: aVE, Ro values of SARS-CoV-2 and the use of non-pharmacological interventions (NPIs). This study found meta-analysis-based aVEs in preventing severe disease and SARS-CoV-2 infection of 56-60% and 36-39%, respectively. Adapted vaccines could not establish herd immunity against the Omicron BA.1 and BA.4-5 variants without using non-pharmacological interventions (NPIs). The adapted vaccines could establish herd immunity only by achieving >80% vaccination coverage, using NPIs with greater effectiveness and when 20-30% of individuals were already protected against SARS-CoV-2 in the population. New adapted COVID-19 vaccines with greater effectiveness in preventing SARS-CoV-2 infection must be developed to increase herd immunity levels against emerging SARS-CoV-2 variants in the population.
dc.format
application/pdf
dc.relation
Vaccines;11(12)
dc.relation
https://doi.org/10.3390/vaccines11121836
dc.rights
Attribution 4.0 International
dc.rights
http://creativecommons.org/licenses/by/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.subject
COVID-19 (Malaltia) - Vacunació
dc.subject
DISEASES::Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections
dc.subject
ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Biological Therapy::Immunomodulation::Immunotherapy::Immunization::Immunotherapy, Active::Vaccination
dc.subject
PHENOMENA AND PROCESSES::Immune System Phenomena::Immunity::Immunity, Herd
dc.subject
ENFERMEDADES::virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus
dc.subject
TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapia biológica::inmunomodulación::inmunoterapia::inmunización::inmunoterapia activa::vacunación
dc.subject
FENÓMENOS Y PROCESOS::fenómenos del sistema inmunitario::inmunidad::inmunidad de grupos
dc.title
Effectiveness of Adapted COVID-19 Vaccines and Ability to Establish Herd Immunity against Omicron BA.1 and BA4-5 Variants of SARS-CoV-2
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion
